BioSpace News Archive

NovaBay® Pharmaceuticals, Inc. announces testing results from an independent third-party laboratory confirming that Avenova®, NovaBay’s proprietary formulation of pure hypochlorous acid, kills SARS-CoV-2.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced a new preclinical research and option agreement with Kansas State University to develop a vaccine candidate for the prevention of COVID-19 that utilizes a novel live virus vaccine vector platform and the CD40-ligand, also known as CD154 or 5c8 antigen, to stimulate T cell immunity.

World-renowned retina specialist to lead EYP-1901 development efforts and support expansion of EyePoint’s ocular disease pipeline

AdCOVID stimulated both strong serum neutralizing activity and potent mucosal immunity (IgA) in the respiratory tract

Angelini Pharma obtains exclusive development, manufacturing and commercialization rights to OV101 (gaboxadol) for the potential treatment of Angelman syndrome in the European Union and other countries in the European Economic Area (Switzerland, Turkey and the United Kingdom) and Russia

Initiative will include first integration of NAVIFY Tumor Board software with OncoEMR system to incorporate electronic medical record information in tumor board reviews

Thermo Fisher Scientific and First Genetics JCS, a manufacturer of diagnostic equipment and IVD kits intended to advance molecular genetic technologies into clinical practice, announced a strategic partnership focused on commercializing next-generation sequencing –based diagnostics in Russia.

A new UC Davis Eye Center study, in collaboration with France’s INSERM Stem Cell and Brain Research Institute, found that special patented glasses engineered with technically advanced spectral notch filters enhance color vision for those with the most common types of red-green color vision deficiency.

Dewpoint Therapeutics, the biomolecular condensates company, announced that it has forged an exclusive collaboration agreement with Merck, known as MSD outside the United States and Canada, to apply Dewpoint’s proprietary platform for condensate-based drug discovery to the development of a novel mechanism for the treatment of HIV.

Premier Inc., through its ProvideGx™ program, has partnered with Fresenius Kabi to supply Diprivan® injectable emulsion, USP to healthcare providers, helping to stabilize the long-term supply of a medication vital for COVID-19 patient care.